<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808301</url>
  </required_header>
  <id_info>
    <org_study_id>PLA-07-01</org_study_id>
    <nct_id>NCT00808301</nct_id>
  </id_info>
  <brief_title>Oat Products in the Treatment of Coeliac Disease in Children</brief_title>
  <official_title>Multicentre Clinical Trial on Oat Products in the Treatment of Coeliac Disease in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinz Italia SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinz Italia SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In many Northern European countries oat-based products have been used in the dieto-therapy of
      coeliac disease for many years.

      The purpose of this study is to evaluate clinical tolerance and liking of gluten-free
      products containing oatmeal from a specific oat variety (not contaminated with gluten) in a
      sample of Italian celiac patients in pediatric age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several clinical trials have demonstrated that most celiac patients, both of pediatric and of
      adult age, can take medium-high quantity of oat (50-100 g/day), without any negative clinical
      effects.

      In a small number of cases intestinal dyspeptic disorders, especially meteorism, can be
      observed, particularly during the first weeks of oat intake. They are generally without
      clinical significance because they are a consequence of the increased fibre intake.

      There are only few cases of &quot;true&quot; oats intolerance. The addition of oat improves the
      nutritional quality of the gluten-free diet, particularly due to the increased intake of
      fibre and some oligoelements (iron, zinc, tiamin, pholates) and expands the spectrum of food
      choices.

      In many Northern European countries oat-based products have been used in the dieto-therapy of
      coeliac disease for many years.

      For the oat-based product to be considered suitable in the dieto-therapy of coeliac disease,
      the absence of gluten contamination and possibly the origin from a variety of oat which is
      without traces of gluten cross-reactive peptides must be guaranteed.

      The purpose of this study is to evaluate clinical tolerance and liking of gluten-free
      products containing oatmeal from a specific oat variety (not contaminated with gluten) in a
      sample of Italian celiac patients in pediatric age.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical safety through serological markers of coeliac disease and intestinal wall integrity, clinical and bioumoral parameters of nutrition status, frequency and clinical type of dyspeptic disorders or other adverse reactions.</measure>
    <time_frame>Controls at recruiting, after 3, 6, 9, 12, 15 months from the beginning of the study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liking of gluten-free products containing oatmeal is evaluated through a product liking questionnaire.</measure>
    <time_frame>Product liking questionnaire after 6 months and 15 months from the beginning of the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Clinical and Nutritional Safety.</condition>
  <arm_group>
    <arm_group_label>A/B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is a cross-over design, i.e. each patient is treated with either oat or control products in different times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gluten-free products</intervention_name>
    <description>Gluten-free bakery products containing oatmeal.</description>
    <arm_group_label>A/B</arm_group_label>
    <other_name>BiAglut</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: the study will include patients aged between 4 and 14, under treatment
        with a gluten-free diet for coeliac disease (bioptic diagnosis) for at least two years.

        Exclusion Criteria:

        diagnosis not confirmed by intestinal biopsy, cases with little adherence to the treatment
        (anti-tTG positive at basal evaluation), cases of potential coeliac disease (completely
        normal mucous membrane), cases with an associated sieric IgA deficit, cases with associated
        diseases (es. diabetes type 1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Catassi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università Politecnica delle Marche - Clinica Pediatrica - Ancona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruggiero Francavilla, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Policlinico Consorziale, Clinica Pediatrica &quot;B.Trambusti&quot; - Bari</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Pittschieler, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Centrale di Bolzano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Basilio Malamisura, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Civile &quot;S. Maria Incoronata dell'Olmo&quot; - Cava de' Tirreni (SA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Panceri, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera &quot;San Gerardo&quot; - Monza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Barbato, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Policlinico Umberto I - Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario La Rosa, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria &quot;Policlinico Vittorio Emanuele&quot; - Catania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Policlinico Vittorio Emanuele&quot;</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile &quot;S. Maria Incoronata dell'Olmo&quot;, Divisione di Pediatria</name>
      <address>
        <city>Cava de' Tirreni</city>
        <state>Salerno</state>
        <zip>84013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Politecnica delle Marche, Clinica Pediatrica</name>
      <address>
        <city>Ancona</city>
        <zip>60123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico Consorziale, Clinica Pediatrica &quot;B.Trambusti&quot;</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Centrale, Divisione di Pediatria</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;San Gerardo&quot;, Clinica Pediatrica</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico &quot;Umberto I&quot; - Dip. di Pediatria - UOC di Gastroenterologia ed Epatologia Pediatrica</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Catassi C. The world map of celiac disease. Acta Gastroenterol Latinoam. 2005;35(1):37-55. Review. English, Spanish.</citation>
    <PMID>15954735</PMID>
  </reference>
  <reference>
    <citation>Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001 Feb;120(3):636-51. Review.</citation>
    <PMID>11179241</PMID>
  </reference>
  <reference>
    <citation>Reunala T, Collin P, Holm K, Pikkarainen P, Miettinen A, Vuolteenaho N, Mäki M. Tolerance to oats in dermatitis herpetiformis. Gut. 1998 Oct;43(4):490-3.</citation>
    <PMID>9824575</PMID>
  </reference>
  <reference>
    <citation>Hoffenberg EJ, Haas J, Drescher A, Barnhurst R, Osberg I, Bao F, Eisenbarth G. A trial of oats in children with newly diagnosed celiac disease. J Pediatr. 2000 Sep;137(3):361-6.</citation>
    <PMID>10969261</PMID>
  </reference>
  <reference>
    <citation>Janatuinen EK, Kemppainen TA, Julkunen RJ, Kosma VM, Mäki M, Heikkinen M, Uusitupa MI. No harm from five year ingestion of oats in coeliac disease. Gut. 2002 Mar;50(3):332-5.</citation>
    <PMID>11839710</PMID>
  </reference>
  <reference>
    <citation>Størsrud S, Olsson M, Arvidsson Lenner R, Nilsson LA, Nilsson O, Kilander A. Adult coeliac patients do tolerate large amounts of oats. Eur J Clin Nutr. 2003 Jan;57(1):163-9.</citation>
    <PMID>12548312</PMID>
  </reference>
  <reference>
    <citation>Lundin KE, Nilsen EM, Scott HG, Løberg EM, Gjøen A, Bratlie J, Skar V, Mendez E, Løvik A, Kett K. Oats induced villous atrophy in coeliac disease. Gut. 2003 Nov;52(11):1649-52.</citation>
    <PMID>14570737</PMID>
  </reference>
  <reference>
    <citation>Högberg L, Laurin P, Fälth-Magnusson K, Grant C, Grodzinsky E, Jansson G, Ascher H, Browaldh L, Hammersjö JA, Lindberg E, Myrdal U, Stenhammar L. Oats to children with newly diagnosed coeliac disease: a randomised double blind study. Gut. 2004 May;53(5):649-54.</citation>
    <PMID>15082581</PMID>
  </reference>
  <reference>
    <citation>Arentz-Hansen H, Fleckenstein B, Molberg Ø, Scott H, Koning F, Jung G, Roepstorff P, Lundin KE, Sollid LM. The molecular basis for oat intolerance in patients with celiac disease. PLoS Med. 2004 Oct;1(1):e1. Epub 2004 Oct 19.</citation>
    <PMID>15526039</PMID>
  </reference>
  <reference>
    <citation>Holm K, Mäki M, Vuolteenaho N, Mustalahti K, Ashorn M, Ruuska T, Kaukinen K. Oats in the treatment of childhood coeliac disease: a 2-year controlled trial and a long-term clinical follow-up study. Aliment Pharmacol Ther. 2006 May 15;23(10):1463-72.</citation>
    <PMID>16669961</PMID>
  </reference>
  <reference>
    <citation>Peräaho M, Collin P, Kaukinen K, Kekkonen L, Miettinen S, Mäki M. Oats can diversify a gluten-free diet in celiac disease and dermatitis herpetiformis. J Am Diet Assoc. 2004 Jul;104(7):1148-50.</citation>
    <PMID>15215774</PMID>
  </reference>
  <reference>
    <citation>Garsed K, Scott BB. Can oats be taken in a gluten-free diet? A systematic review. Scand J Gastroenterol. 2007 Feb;42(2):171-8. Review.</citation>
    <PMID>17327936</PMID>
  </reference>
  <reference>
    <citation>Størsrud S, Hulthén LR, Lenner RA. Beneficial effects of oats in the gluten-free diet of adults with special reference to nutrient status, symptoms and subjective experiences. Br J Nutr. 2003 Jul;90(1):101-7.</citation>
    <PMID>12844381</PMID>
  </reference>
  <reference>
    <citation>Thompson T. Gluten contamination of commercial oat products in the United States. N Engl J Med. 2004 Nov 4;351(19):2021-2.</citation>
    <PMID>15525734</PMID>
  </reference>
  <reference>
    <citation>Hernando A, Mujico JR, Juanas D, Méndez E. Confirmation of the cereal type in oat products highly contaminated with gluten. J Am Diet Assoc. 2006 May;106(5):665; discussion 665-6.</citation>
    <PMID>16647318</PMID>
  </reference>
  <reference>
    <citation>Hollén E, Högberg L, Stenhammar L, Fälth-Magnusson K, Magnusson KE. Antibodies to oat prolamines (avenins) in children with coeliac disease. Scand J Gastroenterol. 2003 Jul;38(7):742-6.</citation>
    <PMID>12889560</PMID>
  </reference>
  <reference>
    <citation>Fasano A, Not T, Wang W, Uzzau S, Berti I, Tommasini A, Goldblum SE. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000 Apr 29;355(9214):1518-9.</citation>
    <PMID>10801176</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coeliac disease</keyword>
  <keyword>Oat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

